Actively Recruiting
Preparing for the Use of a Dengue Vaccine in the French Caribbean Islands of Martinique and Guadeloupe: the DengueSEA Study
Led by University Hospital Center of Martinique · Updated on 2025-02-21
590
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
Sponsors
U
University Hospital Center of Martinique
Lead Sponsor
E
Ecole des Hautes Etudes en Santé Publique
Collaborating Sponsor
AI-Summary
What this Trial Is About
Dengue fever is a mosquito-borne virus that causes significant health problems in tropical and subtropical regions. There is currently no antiviral treatment, and controlling mosquitoes has limitations. The tetravalent Dengvaxia4 vaccine, authorized in Europe in 2018, is used to prevent dengue in people aged 9 to 45 who have had prior dengue infection and live in areas with high infection rates. This study focuses on estimating dengue virus seroprevalence among 9- to 17-year-olds in Martinique and Guadeloupe, where previous data was limited to adults. Researchers will collect blood samples from children aged 9 to 17 who visit participating hospital departments to measure dengue and Zika virus antibodies. The study also includes a survey for parents or guardians to assess their willingness to accept the dengue vaccine and understand factors influencing vaccine hesitancy. This combined approach aims to support optimal vaccine introduction and better healthcare planning in these regions. Participants will provide a blood sample during hospital visits and complete questionnaires. Researchers will test for dengue and Zika antibodies to determine infection history and vaccine eligibility. They will track dengue seroprevalence, incidence of primary dengue infection, changes in infection risk over time, and vaccine acceptability. The study results will help guide dengue vaccination strategies and improve management of future dengue outbreaks. Participation duration averages about one year for outcome measurements and surveys.
CONDITIONS
Brief Title
Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children aged 9 to 17 years attending participating hospital departments
- Need for a blood sample or peripheral venous line as part of care
- Residence in Martinique or Guadeloupe for at least one year
- Study information provided to child and parent or legal guardian
- Parent or legal guardian provides non-objection to participation
You will not qualify if you...
- Presence of fever or suspected acute infection
- Presence of immune deficiency or any other immune condition
- Parents or guardians unable to understand spoken and written French for vaccine acceptability survey
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants who undergo routine care are observed to assess dengue and Zika virus seroprevalence and vaccine acceptability.
1 visit for blood sample collection
Trial Site Locations
Total: 1 location
1
Martinique University Hospital Center
Fort-de-France, Martinique
Actively Recruiting
Research Team
V
Véronique PELONDE-ERIMEE
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here